Key considerations for payer advice

ISPOR 2018 Key considerations for payer scientific advice in the EU


What are the key considerations for seeking payer scientific advice in the EU

Within the EU, there are multiple HTA scientific advice options pharmaceutical companies can take to understand payers’ clinical and economic HTA evidence requirements. The aim of this study is to compare the key aspects companies must consider when seeking HTA scientific advice within France, Germany, Italy and the UK.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.